Status:

WITHDRAWN

High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy

Lead Sponsor:

Mayo Clinic

Conditions:

Metabolic Acidosis

Acute Kidney Injury

Eligibility:

All Genders

18-100 years

Phase:

PHASE4

Brief Summary

Researchers are trying to determine which dialysis solution, low bicarbonate fluid (22 mmol/L) or high bicarbonate fluid (32 mmol/L), is better in subjects with acute kidney injury (acute kidney failu...

Detailed Description

This is a prospective randomized trial that will be conducted at Mayo Clinic in Rochester Minnesota. It will be based on Good Clinical Practice Standards and performed under IRB supervision. This will...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Adult patients (≥ 18 years of age)
  • Ability to obtain informed consent, either from patient or legally authorized representative (LAR)
  • Diagnosis of AKI according to KDIGO definition \[an increase in serum creatinine concentration of greater than or equal to 0.3 mg/dL within the first 48 hours of injury, a relative increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline) within the first 7 days of injury, or a reduction in urine output (\<0.5 mL/kg/h for more than 6 hours)\]
  • CRRT initiated for the first time during current ICU admission.
  • Bicarbonate ≤ 22 mEq/L
  • Arterial pH between 7.05 and 7.25(if an ABG is not available, venous pH must be between 7.00 and 7.20)
  • Exclusion Criteria
  • Pregnancy (women of child-bearing potential must have a negative pregnancy test)
  • Diagnosis of End-Stage renal disease and receiving Hemodialysis or peritoneal dialysis prior to ICU admission (this information will be easily obtained by the nephrology team)
  • Arterial pH \<7.05 or \>7.25 (if an ABG is not available, Venous pH \<7.00 or \>7.20)
  • Potassium level \>6.0 mmol/L
  • Severe acute liver failure meeting all the following criteria):
  • INR \>2
  • AST/ALT more than 500 U/L and
  • Bilirubin more than 12 mg/dL)
  • Previous enrollment in this study

Exclusion

    Key Trial Info

    Start Date :

    May 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2024

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT03846258

    Start Date

    May 1 2019

    End Date

    April 1 2024

    Last Update

    April 28 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic in Rochester

    Rochester, Minnesota, United States, 55905